ProfileGDS5678 / 1454281_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 42% 41% 41% 39% 39% 43% 41% 40% 41% 41% 40% 39% 41% 40% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0019542
GSM967853U87-EV human glioblastoma xenograft - Control 22.9352541
GSM967854U87-EV human glioblastoma xenograft - Control 32.9371841
GSM967855U87-EV human glioblastoma xenograft - Control 42.8332839
GSM967856U87-EV human glioblastoma xenograft - Control 52.8499739
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.0938843
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0105541
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9150640
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9168741
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9261741
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9179240
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.8685139
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9575841
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9242640